MenACWY: Serogroups A, C, W, Y
Registry data
- Menveo - GSK - 2 months to 55 years.
- MenQuadfi - Sanofi - 2 years +.
- Menactra - Sanofi - 9 months to 55 years.
Registry Index
Updated Jan 5, 2026Acute Protocol
Vaccine Safety Registry
Meningococcal Vaccine Safety
Professional safety data on MenACWY and MenB vaccines. Clinical trial outcomes, manufacturer packages (Menactra, Menveo, Bexsero), and long-term surveillance.
Clinical Overview
Professional summary
Meningococcal disease is a severe bacterial pathology capable of inducing rapid clinical decline through meningitis (neural lining infection) and septicemia (acute bloodstream infection).
Despite contemporary antibiotic interventions, the disease maintains a 10-15% mortality rate. Up to 20% of survivors present with permanent sequelae, including cognitive impairment, renal damage, hearing loss, or limb amputations.
Protects against Neisseria meningitidis, the primary cause of bacterial meningitis.
Two distinct registry protocols: MenACWY (serogroups A, C, W, Y) and MenB (serogroup B).
Safety record validated through millions of synchronized clinical doses.
High-risk cohorts require specific shared clinical decision-making protocols.
Available Registry Modules
Vaccine modules
MenB: Serogroup B Protocol
Protocol
- Bexsero - GSK - 2-dose series.
- Trumenba - Pfizer - 2 or 3-dose series.
Analyze specific serogroup coverage and titration logic on official nodes.
Eligibility & Schedules
Protocol triage
MenACWY Protocol
- Preteen initiation (11-12 years)
- Teen booster (16 years)
- First-year collegiate residents
MenB Protocol
- Adolescents (16-23 years)
- Preferred window (16-18 years)
- Complement deficiency cohorts
Contraindications
- Hypersensitivity to previous meningococcal dose
- Acute moderate-to-severe illness state
- Shared decision-making for specific medical conditions
Adverse Reaction Profile
Expected and critical events
Local Reactions
- Localized erythema
- Induration (Hardness)
- Injection site pain
Systemic Profile
- Generalized fatigue
- Cephalalgia (Headache)
- Myalgia / arthralgia
- GI distress (Nausea)
Emergency Protocol
Severe anaphylaxis is statistically exceptional. Seek intervention for angioedema, respiratory distress, urticaria, or tachycardia.
Safety Metadata Analysis
Monitoring summary
2026
Registry Cycle
Millions
Doses Monitored
High
Safety Confidence
Institutional Surveillance
Post-market surveillance through VAERS and FDA systems has identified no unexpected safety concerns. Meningococcal registry modules maintain an exemplary clinical risk-to-benefit profile.
Verified Source: CDC / WHO
Last global review: September 1, 2025. Content verified by HCP Connect clinical editorial staff in alignment with 2026 safety protocols.